![]() The increase in net product sales was attributable to growth across the Company’s commercial products. For the six months ended June 30, 2021, net product sales were $102.0 million, compared to $96.2 million for the same period in 2020. Net product sales for the second quarter of 2021 were $54.6 million, compared to $48.4 million for the same period in 2020. and conditional marketing authorization in Europe.” Next month, we are looking forward to the upcoming topline results from our Phase 3 PROTECT Study of sparsentan in IgA nephropathy, which if successful, would contribute to the growing body of evidence for sparsentan in rare kidney disorders, and potentially support submissions for accelerated approval in the U.S. timelines for FSGS and look forward to our upcoming Type A meeting with the FDA to further our collaborative discussions on the potential to stay on an accelerated approval pathway. As previously announced, we’ve adjusted our U.S. “We are encouraged by recent interactions with EMA, and we remain on-track to submit an application for conditional marketing authorization for FSGS in Europe later this year. “We remain steadfast in our commitment to advancing toward our goal of delivering sparsentan as a potential new treatment standard for people living with FSGS and IgAN,” said Eric Dube, Ph.D., chief executive officer of Travere Therapeutics.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |